Title : CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128.

Pub. Date : 2018 May 25

PMID : 29899840






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 CD44 was significantly increased in Huh7 cells made resistant to sorafenib. Sorafenib CD44 molecule (Indian blood group) Homo sapiens
2 Moreover, a combination of INK128 and sorafenib showed improved anti-proliferative effects in CD44high HCC cells. Sorafenib CD44 molecule (Indian blood group) Homo sapiens
3 Since the clinical response to sorafenib is highly variable, our findings suggest that ATP-competitive mTOR inhibitors may be effective in treating advanced, CD44-expressing HCC patients who are insensitive to sorafenib. Sorafenib CD44 molecule (Indian blood group) Homo sapiens